p 52: interferon beta-a1 vs. teriflunomide for multiple sclerosis
Authors
abstract
multiple sclerosis (ms) is an inflammatory disorder, in which neurons in central nervous system (cns) become demyelinated .ms is named for its formation of plaques due to sclerosis of myelin. variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. it is commonly characterized by recurrent relapses and often followed by severe neurological disabilities. the hallmark of its symptom is optic neuritis, muscular spasms, depression, anxiety and dysphagia. etiology of ms is uncertain. however, it is mostly believed to be an autoimmune disease in which t and b lymphocytes disintegrate oligodendrocytes which are in charge of myelin production. therefore, interferon beta -1a and teriflunomide seem to improve such condition as they inhibit proliferation of leukocytes. nonetheless, there are some inconsistencies concerning their outcome. the aim of this study was to designate one of them to optimal remedy option. 40 percent of the resources regarding teriflunomide denied its potency for prospective treatment as a result of frequent relapse-remitting of ms, as well as liver problems, hair loss, nausea and diarrhea. 20 percent of this category confirmed 90 percent desired result and the rest ensured demanded outcome. on the other hand, though, 100 percent of the resources concerning interferon beta-1a confirmed its efficacy with minor side effects. in a general sense, forthcoming outcome of prescribing interferon beta-a1 for multiple sclerosis patients is foreseen more beneficial.
similar resources
P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...
full textAlemtuzumab vs. interferon beta-1a in early multiple sclerosis.
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. METHODS In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a dis...
full textTeriflunomide for the treatment of multiple sclerosis.
Teriflunomide is a new active drug which has recently been approved as a first-line treatment of relapsing forms of MS in the US, Australia, Argentina, and the European Union. It is characterized by a once-daily oral application and a well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in p...
full textFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
full textMeningioma growth during interferon beta-1A treatment for multiple sclerosis.
Fleury Diagnostic Center, Section of Radiology, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Radiology, São Paulo SP Brazil; Santa Casa de Misericórdia de São Paulo, Section of Neurology, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Neurosurgery, São Paulo SP, Brazil; Santa Casa de Misericórdia de São Paulo, Section of Pathology, São Pau...
full textMy Resources
Save resource for easier access later
Journal title:
مجله علوم اعصاب شفای خاتمجلد ۵، شماره ۲، صفحات ۸۳-۸۳
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023